HHS has awarded $8.3 million to the API Innovation Center to expand domestic manufacturing of two essential hospital medicines: metoprolol and propofol.
The funding will support end-to-end U.S. production of metoprolol for the first time in decades, according to a March 24 news release from the Administration for Strategic Preparedness and Response. With roughly 90% of cardiovascular drugs used in the U.S. sourced from India or China, the investment aims to reduce reliance on foreign suppliers and strengthen the domestic supply chain for medicines used in cardiovascular, surgical and intensive care settings.
The latest award brings total federal investment in the API Innovation Center to more than $22 million. It follows a $14 million grant in September 2024 to support domestic production of three other critical APIs.
The funds were awarded through the Biopharmaceutical Manufacturing Preparedness Consortium.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
